SCHEMBL4493620

SCHEMBL4493620

CC(=O)Cc1ccc(S(=O)(=O)NC2CNCC(C(=O)NCC(c3ccccc3)c3ccccc3)C2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REN P00797 6/20 0.79
POLB P06746 3/20 0.37
KMT2A Q03164 3/20 0.36
ATM Q13315 2/20 0.36
MAPT P10636 1/20 0.36
LMNA P02545 1/20 0.36
MEN1 O00255 2/20 0.35
TSHR P16473 1/20 0.35
ALDH1A1 P00352 3/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CA12 O43570 1/20 0.35
MMP2 P08253 1/20 0.35
MMP9 P14780 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1913218 1.00 REN (0.79) RENPOLBKMT2AATMMAPT
SCHEMBL1913230 0.89 REN (0.86) RENPOLBKMT2AATMMAPT
SCHEMBL1913193 0.88 REN (1.00) RENPOLBMAPTTSHRALDH1A1
SCHEMBL1913201 0.88 REN (0.85) RENPOLBKMT2AATMMAPT
SCHEMBL1913195 0.88 REN (1.00) RENPOLBMAPTTSHRALDH1A1
SCHEMBL1913217 0.87 REN (0.83) RENPOLBKMT2AATMMAPT
SCHEMBL1913222 0.87 REN (0.83) RENMAPTTSHRCA12MMP2
SCHEMBL1913215 0.86 REN (0.79) RENPOLBKMT2AMAPTLMNA
SCHEMBL1913200 0.86 REN (0.81) RENKMT2AMAPTLMNAMEN1
SCHEMBL1913194 0.85 REN (0.80) RENKMT2AMEN1ALDH1A1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233920-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-17 US claimed
EP-1907359-A2 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS Novartis AG (CH) 2008-04-09 EP claimed
WO-2007006534-A2 PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY NOVARTIS AG (CH) 2007-01-18 WO claimed
US-20090233920-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233920-A1 ORGANIC COMPOUNDS REN, ACE, AGTR1 REN 1/4885POLB 748/4885KMT2A 3192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.